Metastatic uveal melanoma (mUM) is a rare disease, and with few effective therapeutic options it is unclear what patients receive as standard of care. Based on national guidelines, we mapped out real-world patient pathways with clinical experts across regional and supra-regional centres across England, to inform a consensus pathway of care following mUM diagnosis.

Adams E, Cheng CY, Sacco J, et. al.  Mapping the treatment pathway for metastatic uveal melanoma (mUM) patients in England: A qualitative pilot study. Society for Immunotherapy of Cancer’s 32nd Annual Meeting. 8-10 November 2017, National Harbour, Maryland, USA.

Read Publication

We assessed the hospital resource use of a cohort of patient with uveal melanoma and metastatic uveal melanoma identified in the Hospital Episode Statistics in England. This showed differences in where patients receive care before and after they develop metastatic disease, indicated a high burden on health care services, and significant travel distances for patients receiving care.

Cheng CY, Alamgir G, Adams EJ, et al. Quantifying standard of care (SoC) hospital-related resource utilisation for metastatic  uveal melanoma (mUM) patients in NHS England (NHSE) using the Hospital Episodes Statistics (HES) dataset. International Society for Pharmacoeconomics and Outcomes Annual European Congress. 4-8 November 2017. Glasgow, Scotland, UK.

Read Publication